Key quarterly metrics and time-series context:\n- Revenue: $662,715; Gross Profit: $662,715; Gross Margin: 100.0% (no cost of revenue reported)\n- Operating Expenses: R&D $1,737,039; G&A $2,629,187; Total Operating Expenses $4,366,226; EBITDA $(3,231,157); Operating Income $(3,703,511); Operating Margin $(5.59)%\n- Net Income: $(1,943,349); Net Margin $(2.93)%; EPS $(0.0083) (diluted)\n- YoY QoQ context: Operating Income YoY change +32.26%; QoQ change -3.80%; Net Income YoY change +64.49%; QoQ change -141.41%; EPS YoY change +81.09%; QoQ change -144.12%\n- Cash flow: Net income $(4,554,424); Depreciation & Amortization $166,121; Stock-based compensation $556,978; Change in working capital $(212,337); Accounts receivable $326,992; Accounts payable $(874,005); Other working capital $334,676; CFO $(3,945,126); Net cash provided by financing activities $5,626,332; Net change in cash $2,024,448; Cash at end of period $10,236,357; Cash at beginning of period $8,211,909; Free cash flow $(3,945,126)\n- Balance sheet and liquidity: Cash and cash equivalents $10,128,400; Total assets $26,470,284; Total liabilities $6,690,016; Total stockholders’ equity $19,780,267; Long-term debt $185,408; Short-term debt $885,266; Total debt $1,070,675; Net debt $(9,057,724) (net cash position)\n- Key leverage and efficiency ratios: Current ratio 2.06; Quick ratio 2.06; Cash ratio 2.04; Gross margin 100.0%; Operating margin −5.59%; Net margin −2.93%; Price-to-sales and related equity multiples reflect a pre-revenue, high-uncertainty biotech profile.